Judge May Reject Merck Vioxx Settlement With 1,700 Australians As Unfair
This article was originally published in PharmAsia News
Executive Summary
An Australia federal judge indicated he may reject a U.S.$556,000 settlement between a class-action group of 1,700 people and Merck over heart problems resulting from its Vioxx (rofecoxib) arthritis drug.